Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13757)	6/2/2000 12:21:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Blue, I do not follow BCHE, neither many antiviral companies, they are risky at best, and HIV treatments are leveling, hepatitis B will dissapeared with vaccines in few years, hep C, is probably the next money maker, but not popular among physicians, it will take time. But BCHE is discounted at a low PE of 20, so long term they should get something or acquire something, they left NVX later pick by BAX. BCHE vaccines are ok business, again they need a new one, NVX acquisition did not work (they did not wanted to go long like bax, they so the UK failure coming, gave it to Bax.) Antivirals: I like RZYM and TRMS, I think they do have truly exceptional and revolutionary technologies, but they are a little pricy, unless one wants to go down 50% to 75% for a while before recovering and doubling tripling cause they went up with the last biotech hype, and they are still in pII studies at best, I missed them both, was in xoma, NO gs.